kabutan

CHUGAI PHARMA, 12% Increase in Net Income for the Last Fiscal Year, Current period performance is undisclosed.

Thu Jan 29, 2026 5:00 pm JST Earnings

4519 CHUGAI PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

CHUGAI PHARMACEUTICAL CO., LTD. <4519> [TSE Prime] announced its financial results (based on IFRS) after the market closed on January 29th (17:00). The consolidated net income for the fiscal year ended December 2025 increased by 12.1% from the previous period to 0.43 trillion yen. Furthermore, the company projects revenue of 1.34 trillion yen for the fiscal year ending December 2026.

At the same time, the company increased the annual dividend for the previous term from 250 yen to 272 yen (compared to 98 yen in the prior term). For the current term, the company plans to remove the commemorative dividend of the previous term and set the dividend for this term at an ordinary dividend of 132 yen.

In the most recent three-month period, from October to December (4Q), the consolidated net income increased 40.2% from the same period last year, reaching 0.12 trillion yen. The operating profit margin rose from 40.9% in the same period last year to 48.8%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 1,111,367 439,174 443,821 325,472 197.8 80 Feb 1, 2024 IFRS
Dec, 2024 1,170,611 542,002 543,034 387,317 235.4 98 Jan 30, 2025 IFRS
Dec, 2025 1,257,941 598,833 597,807 434,012 263.7 272 Jan 29, 2026 IFRS
YoY +7.5% +10.5% +10.1% +12.1% +12.0%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2025 Guidance 1,190,000 ー ー ー － 250 Jan 30, 2025 IFRS
Dec, 2025 Results 1,257,941 598,833 597,807 434,012 263.7 272 Jan 29, 2026 IFRS
Revision Rate +5.7% － － － －

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jan - Jun, 2025 578,463 273,342 271,830 194,389 118.1 125 Jul 24, 2025 IFRS
Jan - Jun, 2026 Guidance ー ー ー ー － 66 Jan 29, 2026 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 1,170,611 542,002 543,034 387,317 235.4 98 Jan 30, 2025 IFRS
Dec, 2025 1,257,941 598,833 597,807 434,012 263.7 272 Jan 29, 2026 IFRS
Dec, 2026 Guidance 1,345,000 ー ー ー － 132 Jan 29, 2026 IFRS
YoY +6.9% － － － －

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 302,073 123,400 125,507 91,559 55.6 40.9 Jan 30, 2025 IFRS
Jan - Mar, 2025 288,459 136,651 135,829 97,234 59.1 47.4 Apr 24, 2025 IFRS
Apr - Jun, 2025 290,004 136,691 136,001 97,155 59.0 47.1 Jul 24, 2025 IFRS
Jul - Sep, 2025 333,177 156,485 156,072 111,213 67.6 47.0 Oct 24, 2025 IFRS
Oct - Dec, 2025 346,301 169,006 169,905 128,410 78.0 48.8 Jan 29, 2026 IFRS
YoY +14.6% +37.0% +35.4% +40.2% +40.2%

Related Articles